Amgen Company Profile (NASDAQ:AMGN)

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen announced a quarterly dividend on Tuesday, March 7th. Stockholders of record on Wednesday, May 17th will be paid a dividend of $1.15 per share on Thursday, June 8th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.55%. The ex-dividend date of this dividend is Monday, May 15th. View Amgen's Dividend History.

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Wednesday, April, 26th. The company reported $3.15 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.15. The firm had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. Amgen had a return on equity of 29.37% and a net margin of 34.42%. Amgen's quarterly revenue was down 1.1% compared to the same quarter last year. During the same period last year, the company posted $2.90 EPS. View Amgen's Earnings History.

Amgen is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for Amgen.

Amgen updated its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share (EPS) guidance of $12.00-12.60 for the period, compared to the Thomson Reuters consensus estimate of $12.34. The company issued revenue guidance of $22.3-23.1 billion, compared to the consensus revenue estimate of $23.02 billion.

23 equities research analysts have issued twelve-month price targets for Amgen's shares. Their predictions range from $161.00 to $209.00. On average, they anticipate Amgen's stock price to reach $185.68 in the next twelve months. View Analyst Ratings for Amgen.

Here are some recent quotes from research analysts about Amgen stock:

• 1. Cowen and Company analysts commented, "Amgen reported Q1 Revenue of $5.46B (-1% Y/Y, vs. consensus of $5.61BE) and." (4/27/2017)
• 2. Cann analysts commented, "Positive data released yesterday for Amgen's cardiovascular drug, Repatha continues to support our growth expectations for Amgen. Amgen announced that four-year follow-up results from the OSLER-1 study were published in JAMA Cardiology. This is the longest PCSK9 inhibitor clinical trial to date. No new safety concerns identified and no neutralizing antibodies observed with cumulative exposure." (3/15/2017)
• 3. BMO Capital Markets analysts commented, "We expect the overall survival (OS) benefit in relapsed myeloma patients to enable Kyprolis to grow in the face of generic competition for Velcade. Upside, however, is in our opinion dependent on data in combination with Revlimid+dex (ECOG Ph3) in newly-diagnosed patients given failure of CLARION. Anecdotal data suggests that Darzalex is best suited in IMiD and proteasome inhibitor failures given lack of response of these agents in patients failing Darzalex." (3/6/2017)
• 4. According to Zacks Investment Research, "Amgen growth products – Prolia, Xgeva, Vectibix, Nplate and Sensipar – are performing well. Amgen’s restructuring plan should make it leaner and more cost efficient. Amgen is also progressing with its pipeline given quite a few regulatory and data updates scheduled for the coming quarters. Amgen has a positive record of earnings surprises in recent quarters. Amgen’s shares surpassed that of Biomed-Genetics industry in 2016. However, the company has some challenges in store given the presence of biosimilar competition and slowdown in sales of mature products. Biosimilars are starting to have a negative impact on key products like Neupogen and Neulasta in the EU. Moreover, minimal sales price increases and stiff competition can hurt blockbuster Enbrel sales in 2017. Estimates have also declined lately ahead of the company’s Q4 earnings release." (1/3/2017)

Some companies that are related to Amgen include Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Exelixis (EXEL), TESARO (TSRO), BIOVERATIV INC (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), BeiGene (BGNE), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO) and Agios Pharmaceuticals (AGIO).

Amgen's management team includes the folowing people:

• Robert A. Bradway, Chairman of the Board, President, Chief Executive Officer
• David W. Meline, Executive Vice President, Chief Financial Officer
• Sean E. Harper, Executive Vice President - Research and Development
• Anthony C. Hooper, Executive Vice President - Global Commercial Operations
• Brian M. McNamee, Executive Vice President - Full Potential Initiatives
• Esteban Santos, Executive Vice President, Operations
• Cynthia M. Patton, Senior Vice President, Chief Compliance Officer
• Jonathan P. Graham, Senior Vice President, General Counsel, Secretary
• Lori A. Johnston, Senior Vice President
• David A. Piacquad, Senior Vice President - Business Development

Amgen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.37%), APG Asset Management N.V. (0.22%), NN Investment Partners Holdings N.V. (0.12%), US Bancorp DE (0.10%), AMF Pensionsforsakring AB (0.09%) and Chevy Chase Trust Holdings Inc. (0.09%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton, David Baltimore, Fred Hassan, Madhavan Balachandran and Sean E Harper. View Institutional Ownership Trends for Amgen.

Amgen's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Assenagon Asset Management S.A., Bank of Montreal Can, NN Investment Partners Holdings N.V., Douglas Lane & Associates LLC, US Bancorp DE, Meag Munich Ergo Kapitalanlagegesellschaft MBH and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Amgen stock in the last year include Annette Louise Such and Cynthia M Patton. View Insider Buying and Selling for Amgen.

Amgen's stock was bought by a variety of institutional investors in the last quarter, including First Quadrant L P CA, Mn Services Vermogensbeheer B.V., Grimes & Company Inc., National Pension Service, Manning & Napier Advisors LLC, Swedbank, Aperio Group LLC and Sprott Inc.. View Insider Buying and Selling for Amgen.

Shares of Amgen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Amgen stock can currently be purchased for approximately $180.21.